Journal article
Cost Effectiveness of Leukotriene Receptor Antagonists versus Long-Acting Beta-2 Agonists as Add-On Therapy to Inhaled Corticosteroids for Asthma
Abstract
Background: Information is lacking on the relative effectiveness and cost effectiveness — in a real-life primary-care setting — of leukotriene receptor antagonists (LTRAs) and long-acting β2 adrenergic receptor agonists (β2 agonists) as add-on therapy for patients whose asthma symptoms are not controlled on low-dose inhaled corticosteroids (ICS).Objective: To estimate the cost effectiveness of LTRAs compared with longacting β2 agonists as …
Authors
Wilson ECF; Price D; Musgrave SD; Sims EJ; Shepstone L; Murdoch J; Mugford HM; Blyth A; Juniper EF; Ayres JG
Journal
PharmacoEconomics, Vol. 28, No. 7, pp. 597–608
Publisher
Springer Nature
Publication Date
7 2010
DOI
10.2165/11537560-000000000-00000
ISSN
1170-7690
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
Administration, InhalationAdolescentAdrenal Cortex HormonesAdultAgedAged, 80 and overAsthmaChildCost-Benefit AnalysisHumansLeukotriene AntagonistsMiddle AgedQuality-Adjusted Life YearsTreatment OutcomeUnited KingdomYoung AdultAdrenergic beta-2 Receptor AgonistsAdrenergic beta-AgonistsDelayed-Action PreparationsDrug Therapy, CombinationSurveys and Questionnaires